Roivant Sciences Ltd.
ROIV
$36.36
$0.060.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -42.78% | 26.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -42.78% | 26.06% | |||
| Cost of Revenue | 1.52% | 19.98% | |||
| Gross Profit | -2.09% | -19.91% | |||
| SG&A Expenses | -4.36% | -1.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.21% | 9.15% | |||
| Operating Income | 0.93% | -9.05% | |||
| Income Before Tax | -164.87% | 256.39% | |||
| Income Tax Expenses | -104.02% | 321.54% | |||
| Earnings from Continuing Operations | -181.69% | 213.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 291.03% | -210.33% | |||
| Net Income | -162.65% | 213.95% | |||
| EBIT | 0.93% | -9.05% | |||
| EBITDA | 0.92% | -9.08% | |||
| EPS Basic | -161.04% | 213.08% | |||
| Normalized Basic EPS | 58.57% | -68.80% | |||
| EPS Diluted | -194.07% | 173.38% | |||
| Normalized Diluted EPS | 52.06% | -45.88% | |||
| Average Basic Shares Outstanding | 2.66% | 0.76% | |||
| Average Diluted Shares Outstanding | -11.27% | 16.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||